Norway: No high-dose omega-3 adverse effects

By Shane Starling

- Last updated on GMT

No serious adverse effects at high doses of omega-3s, conclude Norwegian authorities
No serious adverse effects at high doses of omega-3s, conclude Norwegian authorities
Norwegian authorities have conducted a safety review of omega-3 forms EPA and DHA and found no adverse effects up to levels as high as 6.9g per day for certain conditions – a level far in excess of recent German recommendations of 1.5g/day.

The Norwegian Scientific Committee for Food Safety (VKM) surveyed dosage levels and effects for a host of conditions including bleeding times; lipid peroxidation; inflammation and immunity; glucose metabolism and gastrointestinal disturbances.

After surveying the literature, they found that adverse effects were not present below 6.9g for bleeding times and concluded: "no tolerable upper intake level could be established."

“Overall, the report supports the assertion that normal intakes of EPA and DHA are safe, and even at the higher pharmaceutical dosages in use today, only minor issues have been observed,”​ said omega-3 trade group, the Global Organization for EPA and DHA Omega-3s (GOED).

Other negative effects were referenced in selected trials at 3.5g for lipid peroxidation; 5g for certain inflammation markers and 6g for gastrointestinal issues.

No need for an upper intake level

“Negative health effects regarding gastrointestinal function, including abdominal cramps, flatulence, eructation, vomiting and diarrhea, have been reported, but seem to be associated with intake of an oily substance and not ascribed specifically to EPA and/or DHA,”​ the VKM report concluded.

“Based on the reviewed literature, it is not possible to identify clear adverse effects from EPA and/or DHA, which can be used for setting tolerable upper intake levels.”

Of ALA it said: “In the studies investigating ALA, no negative health effects have been observed. Intake of ALA from linseed oil and margarine up to 8g/day in addition to the contribution from a Western diet has not shown any negative health effects and it is therefore no rationale to set an upper tolerable intake level for ALA.”

But it said omega-3 health benefits were down to EPA and DHA, not ALA directly.

The report can be found here.

Related news

Show more

Related products

show more

Research for Restorative Sleep: Levagen®+

Research for Restorative Sleep: Levagen®+

Content provided by Gencor | 27-Sep-2024 | White Paper

Levagen®+ is Gencor's branded Palmitoylethanolamide (PEA), an endogenous fatty acid amide naturally found in every cell of the body.

Comprehensive Nutritional Lipid Solutions

Comprehensive Nutritional Lipid Solutions

Content provided by INNOBIO Corporation Limited | 24-Sep-2024 | White Paper

INNOBIO specializes in high-quality DurOmega® functional lipid products, emphasizing enhanced fatty acid quality and application performance.

Research for Restorative Sleep: Levagen®+

Research for Restorative Sleep: Levagen®+

Content provided by Gencor | 09-Sep-2024 | White Paper

Levagen®+ is Gencor's branded Palmitoylethanolamide (PEA), an endogenous fatty acid amide naturally found in every cell of the body.

Research to Reality: Restorative Sleep

Research to Reality: Restorative Sleep

Content provided by Gencor | 02-Sep-2024 | White Paper

Gencor prides itself on its cutting-edge, science-driven solutions. Explore sleep support through gold-standard, clinically-validated dietary supplement...

Related suppliers

Follow us

Products

View more

Webinars